ReviewInternational journal of molecular sciences2020
Targeting of CD163
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 2 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- The tumour microenvironment in paediatric rhabdomyosarcomas: a systematic review.Carcinogenesis · 2025Pooled it
- Prognostic Role of CD68British journal of biomedical science · 2023Pooled it
- Single-cell transcriptomics provides insights into the stress-immune interplay and informs disease risk.Cell genomics · 2026Article
- Ligation of the CD163 molecule inhibits the synthesis of type I and type III interferons in porcine alveolar macrophages.BMC veterinary research · 2026Article
- Liver Macrophages in the Pathogenesis of Viral Hepatitis.Current issues in molecular biology · 2026Review
- Targeting Post-Irradiation Thyroid Dysfunction: Electrospun Scaffolds As A Dual-Action Approach for Antioxidant and Immune Modulation.Advanced healthcare materials · 2026Article
- Neuroimmune Correlates of HIV and Marijuana Use: Peripheral Biomarkers and Cognitive Function.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Single-cell RNA sequencing in ovarian cancer: decoding the tumor microenvironment for personalized therapy.Journal of ovarian research · 2026Review
- Cell-Specific Extracellular Vesicles Targeting Strategies for Immune Modulation in Inflammatory Diseases.Pharmaceutics · 2026Review
- Modular design for drug delivery across hierarchical gastrointestinal barriers: From materials to systems.Materials today. Bio · 2026Review
- Review
- NOD2 activation reprograms infiltrating inflammatory monocytes in the Zika virus infected CNS to maintain neural correlates of learning and memory.bioRxiv : the preprint server for biology · 2026Article
- Integrated Single-Cell and Bulk RNA Sequencing Identifies Macrophage Heterogeneity and Mitophagy-Related Biomarkers in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2026Article
- Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory Diseases.Biomedicines · 2026Review
- Unraveling the multidimensional pleural ecosystem of lung cancer-associated malignant pleural effusion.Cancer cell international · 2026Review
- Distribution and prognostic value of macrophages in colorectal cancer and adjacent mucosa in patient stages I-IIIWorld journal of gastroenterology · 2026Article
- First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.Journal for immunotherapy of cancer · 2026Article
- Serum sCD163 indicates disease severity and prognosis in sudden sensorineural hearing loss.Molecular medicine (Cambridge, Mass.) · 2026Article
- Characterization of tumour microenvironment in thymic epithelial tumours of different histological subtypes.Discover oncology · 2026Article
- Prenatal corticosteroid exposure disrupts vascular-immune interactions and impairs steroidogenesis in the fetal testis.bioRxiv : the preprint server for biology · 2026Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The macrophage is a key cell in the pro- and anti-inflammatory response including that of the inflammatory microenvironment of malignant tumors. Much current drug development in chronic inflammatory diseases and cancer therefore focuses on the macrophage as a target for immunotherapy. However, this strategy is complicated by the pleiotropic phenotype of the macrophage that is highly responsive to its microenvironment. The plasticity leads to numerous types of macrophages with rather different and, to some extent, opposing functionalities, as evident by the existence of macrophages with either stimulating or down-regulating effect on inflammation and tumor growth. The phenotypes are characterized by different surface markers and the present review describes recent progress in drug-targeting of the surface marker CD163 expressed in a subpopulation of macrophages. CD163 is an abundant endocytic receptor for multiple ligands, quantitatively important being the haptoglobin-hemoglobin complex. The microenvironment of inflammation and tumorigenesis is particular rich in CD163
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.